NSAID use and the risk of parkinsons disease: Systematic review and meta-analysis of observational studies

Drugs and Aging

Volumn 26, Issue 9, 2009, Pages 769-779

  Samii, Ali ^a,d   Etminan, Mahyar ^b   Wiens, Matthew O ^b,c   Jafari, Siavash ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Chilliwack General Hospital   (Canada)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; NEUROPROTECTIVE AGENT;

ARTICLE; CLINICAL TRIAL; DRUG USE; HUMAN; MEDLINE; META ANALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SEXUAL DEVELOPMENT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; ODDS RATIO; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SEX CHARACTERISTICS;

EID: 69949164871     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11316780-000000000-00000     Document Type: Article

References (28)

1. Samii A, Nutt JG, Ransom BR. 2004; 363: 1783-1793
2. Litvan I, Chesselet MF, Gasser T, et al. The etiopatho-genesis of Parkinson disease and suggestions for future research: part II. J Neuropathol Exp Neurol 2007; 66 (5): 329-336 (Pubitemid 46701314)
3. Schapira AH. Mitochondria in the aetiology and patho-genesis of Parkinson's 97-109
4. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's 991: 120-131
5. Monahan AJ, Warren M, Carvey PM. Neuroinflammation and peripheral immune infiltration in an autoimmune hypothesis. Cell Transplant 2008; 17 (4): 363-372
6. McGeer PL, McGeer EG. Glial reactions in disease. Mov Disord 2008; 23 (4): 474-483
7. Asanuma M, Miyazaki I. Common anti-inflammatory drugs are potentially therapeutic for Exp Neurol 2007; 206 (2): 172-178
8. Bower JH, Maraganore DM, Peterson BJ, et al. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study. Neurology 2006; 67 (3): 494-496
9. Etminan M, Suissa S. NSAID use and the risk of Parkinson's
10. Hernán MA, Logroscino G, Garcia Rodriguez LA. Non-steroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology 2006; 66 (7): 1097-1099
11. Ton TG, Heckbert SR, Longstreth Jr WT, et al. Non-steroidal anti-inflammatory drugs and risk of disease. Mov Disord 2006; 21 (7): 964-969
12. Hancock DB, Martin ER, Stajich JM, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007; 64 (4): 576-580
13. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Mov Disord 2008; 23 (1): 88-95
14. Wahner AD, Bronstein JM, Bordelon YM, et al. Non-steroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007; 69 (19): 1836-1842
15. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal antiinflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60 (8): 1059-1064
16. Chen H, Jacobs E, Schwarzschild MA, et al. Nonsteroidal antiinflammatory drug use and the risk for disease. Ann Neurol 2005; 58 (6): 963-967
17. Bornebroek M, de Lau LM, Haag MD, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Neuroepidemiology 2007; 28 (4): 193-196
18. Etminan M, Carleton BC, Samii A. Non-steroidal antiinflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. J Clin Neurosci 2008; 15 (5): 576-577
19. Parepally JM, Mandula H, Smith QR. Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbi-profen, and indomethacin. Pharm Res 2006; 23 (5): 873-881
20. Casper D, Yaparpalvi U, Rempel N, et al. Ibuprofen pro- disease. Lancet tects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 2000; 289 (3): 201-204
21. Kurkowska-Jastrzebska I, Czonkowski A, Czonkowska A. Ibuprofen and the mouse model of Ann Neurol 2006; 59 (6): 988-989
22. Elsisi NS, Darling-Reed S, Lee EY, et al. Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett 2005; 375 (2): 91-96
23. Braak H, Del Tredici K. Nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70 (20): 1916-1925
24. Schapira AH. Progress in neuroprotection in disease. Eur J Neurol 2008; 15 Suppl. 1: 5-13
25. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005; 64 (2): 208-215
26. McGeer EG, McGeer PL. The role of anti-inflammatory agents in 789-797
27. Tansey MG, Frank-Cannon TC, McCoy MK, et al. Neuro-inflammation in evidence for mechanism-based interventional therapy? Front Biosci 2008; 13: 709-717
28. Klegeris A, McGeer EG, McGeer PL. Therapeutic approaches to inflammation in neurodegenerative disease. Parkinson's Curr Opin Neurol 2007; 20 (3): 351-357